

Exton, Adam (HC/SC)

From: Bridget Howe <bhowe@counselpa.com>
Sent: 2020-10-07 11:46 AM
To: Ryan Lock; Nowers, Kathryn (HC/SC); Bakht, Tahiya (HC/SC)
Cc: Sheamus Murphy
Subject: RE: GSK/Sanofi/Government of Canada C-19 Vaccine Announcement & GSK's Federal Pre-Budget Submission

Good morning,

I wanted to follow up on Ryan's email below to see if one of you may be available for a short conversation regarding the important work that GSK is doing in the vaccine space and input on the National Immunization Strategy. We would be happy to meet sometime this week or next at your convenience.

Best,

Bridget



Bridget Howe
Senior Consultant, Federal Advocacy
95 St. Clair Avenue West, Suite 1606, Toronto, ON, M4V 1N6
P: 416.920.0716 x254 | C: 613.797.8058 [counselpa.com](mailto:bhowe@counselpa.com)

From: Ryan Lock
Sent: September 24, 2020 1:14 PM
To: kathryn.nowers@canada.ca; tahiya.bakht@canada.ca
Cc: Sheamus Murphy ; Bridget Howe
Subject: GSK/Sanofi/Government of Canada C-19 Vaccine Announcement & GSK's Federal Pre-Budget Submission

Kathryn & Tahiya,

Good afternoon. I wanted to reach out regarding Minister Anand's important COVID-19 vaccine announcement from earlier this week, as well as GSK's recent pre-Budget submission, which concerns NACI-recommended (but in some cases unfunded) vaccines for seniors and older adults.

As you know, GSK is collaborating with several companies and research groups across the world, including Sanofi, on promising COVID-19 vaccine candidates through the use of our pandemic adjuvant technology. Earlier this week, Minister Anand announced that GSK and Sanofi have signed respective agreements with the Government of Canada to supply up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. This will enable Canadians to have access to a COVID-19 vaccine candidate, it and reflects our commitment and global efforts to tackle the virus. Both companies have vaccine manufacturing sites in Canada that are contributing to overall global COVID-19 vaccine development, and these plus global industrial networks will play a pivotal role in the production of the COVID-19 vaccine. I've included a link to the GSK press release here: <https://www.gsk.com/en-gb/media/press-releases/sanofi->

[and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine/](#)

Clearly, the pandemic spread of COVID-19 has raised awareness of the potentially devastating impact of infectious disease outbreaks on individuals – especially seniors and other at-risk populations – and challenged the resilience of healthcare systems. This impact is of course not limited to COVID-19. Other diseases – including a number of vaccine-preventable diseases – are responsible for a burden of illness and death that rivals or surpasses COVID-19.

With this in mind, GSK has submitted a pre-Budget submission calling on the federal government to refresh the National Immunization Strategy, which has not been updated since 2003. And also to allocate funding to ensure equitable access to NACI-recommended adult vaccines to Canadians from coast-to-coast-to-coast. We would of course be pleased to meet with you at your convenience to discuss this proposal and any questions you may have.

Thank you for your consideration. //RL

Ryan W. Lock, MPA

Lead – Federal Affairs and Public Policy

7333 Mississauga Road North
Mississauga, ON L5N 6L4
Tel (416) 574-5014

[gsk.com](#) | [Twitter](#) | [YouTube](#) | [Facebook](#) | [Flickr](#)



GSK surveille les courriels reçus et envoyés pour se protéger, pour protéger ses employés, clients, fournisseurs et partenaires commerciaux contre les cybermenaces et pour éviter la perte de ses données. La surveillance de GSK s'exerce selon des contrôles de confidentialité appropriés, conformément aux lois locales et à la suite d'une consultation appropriée.

If you previously subscribed to receive commercial electronic messages from GlaxoSmithKline Inc. and no longer wish to receive them, please click here to unsubscribe: <http://casl.gsk.ca/> Si vous avez déjà consenti à recevoir les messages électroniques commerciaux de GlaxoSmithKline Inc. et ne souhaitez plus les recevoir, veuillez cliquer ici pour vous désabonner: <http://casl.gsk.ca/fr-ca/>

GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.